The "lowest price in Europe" for Sovaldi announced by the French Health Ministry yesterday -- $51,373 for a 12-week treatment -- makes your $25,000 EU estimate for the ABBV/ENTA regimen appear quite "doable". And Harvoni is still under negotiation with the French, but it has a temporary approval price of about $60,000 for a 12-week course.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.